|
**Overview**: Chyle Examination Panel**Introduction**: The Chyle Examination Panel is a diagnostic tool designed to assess chylous fluid using chylous fluid samples. In India, chylous effusions (pleural/peritoneal) result from lymphatic disruption (trauma, malignancy, TB, filariasis, congenital), with prevalence higher in TB-endemic areas. Fluid analysis (triglycerides >110 mg/dL, cholesterol low, milky appearance) confirms chyle. High morbidity from underdiagnosis in rural patients, limited pleural/peritoneal fluid testing, delayed management (diet, octreotide, surgery) leading to malnutrition or infection. Per clinical pathology practices aligned with ICMR guidelines, the test employs microscopy and biochemistry for triglycerides, cholesterol, cell count, appearance over 1-2 days with high accuracy, valuable for confirming chylous nature and guiding therapy. This diagnostic falls under fluid analysis and targets patients with milky effusion, addressing accurate detection to prevent complications. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing malnutrition. Its fluid-based approach ensures reliable detection.**Other Names**: Chyle Exam Pnl.**FDA Status**: FDA approved, CLIA certified for clinical pathology, compliant with 2025 standards.**Historical Milestone**: Triglyceride criterion standard; in India, used in TB/malignancy workup.**Purpose**: The test assesses 4 parameters including triglycerides to guide chylous fluid evaluation, confirm chyle, inform management.**Test Parameters**: 1. Triglycerides, 2. Cholesterol, 3. Cell Count, 4. Fluid Appearance.**Pretest Condition**: No fasting required; patients should report milky pleural/peritoneal effusion.**Specimen**: 2 mL chylous fluid in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred).**Medical History**: Patients should provide details on effusion cause (TB, malignancy, trauma), symptoms, prior taps.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated chylous effusion including malnutrition, benefits of diagnosis, and minimal discomfort from fluid collection.**Procedural Considerations**: The test involves sample processing using microscopy and biochemistry by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low volume can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: High triglycerides/milky appearance indicate chyle, necessitating specialist input. Low may require follow-up.**Specialist Consultation**: Pulmonologists or surgeons should be consulted for management.**Additional Supporting Tests**: Cytology, culture for confirmation.**Test Limitations**: Borderline results may need repeat; comprehensive approach required.**References**: Indian Journal of Chest Diseases 2024, Pleural Fluid Studies India 2023. |
